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ABSTRACT
We synthesized a novel anticancer agents based on mixed chelate copper (II) complexes, named
Casiopeinas
(R) has of general fommla [Cu(N-N)(N-O)H20]NO3 (where, N-N diimines as 1,10-
phenanthroline, 2,2-bipyridine, or substituted and N-O=aminoeidate or [Cu(N-N)(O-O)H20]NO3 (where N-
N=diimines as 1,10-phenanthroline, 2,2-bipyridine or substituted Casiopeinas I, II, IV, V, VI, VII VIII and
O-O=acetylacetonate, salicylaldehidate Casiopeinas III). We evaluated the in vitro antitumor activity using
a human cancer cell panel and some nurine cancer cells. Eleven Casiopeinas are evaluated in order to
acquire some structure-activity conelations and some monodentated Casiopeina"s analogues; cisplatinum
was used as control drug. The 50% growth inhibition observed is, in all cases reach with concentrations of
Casiopeina’s 10 or 100 times lower than cisplatinum In a previous work we reported the induction of
apoptosis by Casiopeina II. The results indicate that Casiopeinass are a promising new anticancer drag
candidates to be developed further reward clinical trials.
INTRODUCTION
A series of Cu (II) mixed chelate compounds Casiopeinas
(R) has been nthesized, characterized, patented (1,
2, 3, 4) and X...ray structures solved, when proper cystals were obtained (5), stability constants determined
and EPR study has been done (6).
The general formula of Casiopeinas is [Cu(N-N)(N-O)Hg_O]NO3 (where, N-N diimines as 1,10-
phenanthroline, 2,2-bipyridine, or substituted and N-O=aminocidate or [Cu(N-N)(O-O)H20]NO3 (vhere,
N-N=diimines as 1,10-phenanthroline, 2,2obipyridine or substituted Casiopeinas I, II, IV, V, VI, VII VIII
and O-O=acetylacetonate, salicylaldehidate Casiopehaas III). The design of the molecules was based in
three main factors: the comlx)unds should contain an essential metal for diminish toxici.ty; contain chelates
that favor the cis-configuration around the metal ion and the mixed chelates that contain different level of
hydrophobicity. Casiopeinas were design to have antitumor activity, based on previous works in
cisplatinum and other transition metal series. These reported compounds are proposed to present some
degree of DNA-interaction.
A preliminary report of antineoplastic activity was presented (7), also SOD like activity
and the induction of apoptosis has been reported (8, 9). Casiopefnas have shown
cytotoxicity in several munne tumoral cell lines and strong in vivo antitumor activity in
routine tumoral models in our preliminar results (10).
qqae present study was designed to evaluate the in vitro antitumor activity of several Casiopeinas against
various human and routine tumoral cell lines and to observe a correlation of activity as a function of the
peripherical substituents on the ligands. The in vitro test is one of the most adequate methods to evaluate
anticancer activity in a large range of compounds. In Figm’e the structure of Casiopema III-I is shown as
the perchlorate salt (6).
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Figure 1. Structure of Casiopeina III-I, (4,4-dimethyl, 2,2-bipyridine) (acetylacetonate)
copper (II) perchorate (6)
MATERIALSAN METHOD
CASIOPEINAS were synthes)zed tbllowing the methodology reported in the Patents
(1)..Equimolecular soluuon of the CuNO3 and the coesponding diimine are mixed
tggether followed by an equimglecular aqueous solution of die charged ligand, previously.
deprotonated. The resulting solution is concentrated and the solid obtained is filtered anal
recristallized several times.
Studied Drus
Casiopefna Fgly- Aqua (4,7-diphenyl- 1,10-phenanthroline) (gly.cine) copper_(II)Nitrate.
Casiopefna Iser- Aqua (4,7-diphenyl-l,10-phenanthroline) (sedne) copper (II) Nitrate.
Casiopefna Ilgly- gqua (4,7-ffmet,layl-l,ld-phenanthroline) (glycine) copper (II) Nitrate.
Casiopeina Ilgly- Aqua (4,7-_dimetlayl-1,10-phenanthroline) (sei-ine) copper (H) Nitrate.
Casiopefna IIr-l- (4,:4-dimethyl, 2,2-bil:yrid-lne) (acetylacetonate). copper (II) Nitrate.
C.asiopefna Ill-E- (4,7-dimethyl-l,I0-phenanthrolme) (acetylacetonate) copper (II)
Nitrate.
Casiopefna
Casiopefna II-I 5acac- Aqua (5-nitro-l,10-phenanthrolir/e) (acetylacetonate) copper (II)
Nitrate.
Casiopefna Vser- Aqua (5-nitro-l,10-phenanthroline) (serine) copper (II) Nitrate.
Control drug
CDDP-Cis-aiammine-dichloro-platinum (II)
Monochelates copper compounds
Copper Nitrate
128Bis ,qua (4,7-dihaethyl, 1,10-phenanthroline) copper Nitrate.
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133Bis A,qua (5-nitro-l,lO-phenanthroline) copper (II) Nitrate.
131Bis A,qua (4,4-dimethyl, 2,2-bipyridine) copper (II) Nitrate
134Bis ,qua (glyci.ne) copper (II) Nitrate
135Bis Aqua (acetylacetonate) copper (II) Nitrate
All starting materials and CDDP were commercial and used without further purification.
CELL LINES
Cancer Cell Line Panel. To evaluate drags tbr the cell growth inhibition profile, we
established a human cancer cell line or munne tumoral cell-line from the panel described
(11). With this system we have examined the antiproliferative effect of the Casiopefnas,
andbasal contror drugs mentioned above.
Human: HeLa (adenocarcinoma Stage IV A), SiHa (carcinoma Stae IIIB), CaS.ki
(carcinoma Stage II B), C33-A (carcinoma Stage III A), were obfained from tlae
American Type Culture Collection and CaLo (carcinoma Stage II B) and InB1 were
cloned from biop.sies .o.f patients lrom the National Cancer Institute-Mexico and
generously donatei:l for tlais project (12).
Murine: B 16 Melanoma and Lewis Lung Carcinoma were obtained from the American
Type Culture Collection (12).
Measurements of Cell Growth Inhibition. From a stock culture cell obtained from each cell line cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% of fetal bovine serum (FBS), at 37
C in humidified air containing 5 % CO.,_, a cell dilution of 106 cells/ml is prepared. From this solution, a
volume of 20 tl is added to each well of the microplate in order to obtain 2,104 cells/well. Previously, each
well must contain 100 lal of RPMI 1640 and 10% FBS, then the cells are incubated at 37 C and 5 % of
CO_ for 24 hours. This procedure is in order to allow the cells to attach to the bottom of the well. After the
24 hours, the cells m’e already attached, and lhe medium and FBS are vacuumed from the wells and then
added with 90 lal of DMEM with 10% of FBS mad 10 lal of the four different concentrations of the drugs
(Casiopeinas), basal control drugs or CDDP: 100 lag/ml, 10 lag/ml, [ag/m and 0.1 lag/ml, one well is not
added with drags and it is the proliferation control. Then are incubated for 24 hours. After the time of
incubation, the medium is vacuumed, the cells are fixed with 200 1 of trichloroacetic acid at 10 k over
lhour at 4C. Finally the cells are washed 5 times with regular water and left to dry. at room temperature
and then stained with I(X) 1 of sulforhodamine-B at. 0.4% to each one of the wells containing the cells and
incubated for 30 min at room temperature. Then are washed 4 times with acetic acid at 1%, eliminating it
after been washed, are left to dry at room temperature. When the stain has been incorporated to the cells, it
is solubilized with 100 tl of tris base 10mM (pH 10.5) during 5 minutes with stimng. Finally the stained
cells are readed at 564 nm. Each test is repeated three times (13, 14).
The details of measuring cell grovJa inhibition are described elsewhere (citas26 del articulo). Briefly, the
cells were plated at proper density in 96-well plates with DMEM and 10% of FBS and allow to attach for
24 hr.. The cells were exposed to drugs (Casiopeinas, Blanks and conlrol &’ug) for 24 hr. Then the cell
growth was determined according to the sulforhodamine B assay, described by Skehan (28del articulo).
Data calculations were made according to the method described previously (26 de art). Absorbance for the
control well (C) and the test well (T) were measured at 564 nm. Moreover, at time 0 (addition of the drugs),
absorbance for the test well (To) was also measured. Using these measurements, cell growth inhibition
(percentage of growth) by each concentration of drug was calculated as: % growth =100 X [(T- T0)/(C-
To)], when T > To mad % growth=100 X [(T- To)/T], when T < To. By using the computer to process %
growth values, the 50% ga’owlh inhibition parameter (Gls0) was determined. The GI50 was calculated as 100
X [(T- To)/(C- To)] 50 (15).
RESULTS AND DISCUSSION
The general project for de ’eloping new drugs is showed in the flow diagram Diagram I.
In this work we present the in vitro evaluation over Human and Murine Tumoral Cell
Lines.
The Casiopeinas chosen tbr this studv are those that are selection of the different diim,ines
with the porpuse of observe the effedt of the same charge ligand, as glycine with several
diimines, then we kept the same aminoacidate and observe the effect of the diimine. Also
we have synthesized and tested some monochelates copper complexes in order to observe
if the diss6ciated complex may present some activity.
The results on GI50 (Growth Inhibition) prod,ucedby the several Casiopeinas over the
Uterine Cervix Human Tumoral Lines are sho n in Table I.
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DIAGRAM. 1. Flow diagram R)r the development of Casiopeinas.
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The results from Table I are shown in Plot
Table 2
Casiopeina
III-I
III-E
iVgly
Vnitro-ser
,II-gly
II-ser
Vnitro gly
,Cisplatin
BI6 Melanoma
lag/ml
10761.5
35.83
126.33
10960
55.71
28.13
0.33
30.7
0.18
Lewis Lung Carcinoma
1988.5E5
51.68
285.38
1.25
1.055
1.890
188.24
5.19E5
7.16
0.74
0.03399
0.02666
0.04775
0.63
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The results on GI50 (Growth Inhibition) produced by the several Casiopeinas over the Murine Tumoral
Cell Lines are shown in Table II. These results are depicted in plot 2
’201 100
8O
.- 60
Plot2. Effect of drugs in SiHa
40
20
0
0.01
Table 3
0.1
Concentration mglml
10
Basal control
128 Bis Aqua (4,7-dimethyl,
1,10-phenanthroline) copper
(II) Nitrate.
129 Bis Aqua (4,7-diphenyl,
1,10-phenanthroline) copper
(II) Nitrate
130
131 Bis Aqua (4,4-dimethyl,
2,2-bipyridine) copper (II)
Nitrate
132
133 Bis Aqua (5-nitro-I, 10-
phenantl-oline) copper (II)
Nitrate.
134 Bis Aqua (glycine)
copper (II) Nitrate
G150 (lag/ml) HeLa
121.4.
1315.02,
26.01.
190.25.
106.66.
135Bis Aqua
(acetylacetonate) copper (II)
Nitrate
Dissolved in water. ** Dissolved in DMSO.
G150 (tg/ml) SiHa
10,80.
197.63,
24.93*
679.1,*
G150 (xg/ml) LL
Carcinoma
288.98* / 3.29**
41496.91.
48.72v
32.91.
The % of Inhibition lbr each Cell Line are shown in Plots 3-8 are shown the results for the differents
tumoral cell lines.
24Metal BaaedDrga VoL 8, Nr. 1, 2001
The resnlts in G150 (Growth Inhibition) produced by file Basal Controls over t-lnman and Mm’ine Tmnoral
Cell Lines are shown in Table III. For these basal :onta’ols the Hmn,’m Tumoral Cell I,ines used were HeLa
and SiFla and the Mufine Tumoral Cell I.ines was Lewis Lung Carcinoma
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CONCLUSIONS
At the end of the experiments we conclude that:
The Casiopeinas showed antineoplastic activity in all the different human and murine cell lines, however,
this activity is higher for the cervic-uterine human tumoral cell lines.
The Casiopeinas with symmetric phenanthrolines, especially with substituents at 4, 7 positions showed
more activity than those with substitution in 5 position. Regarding to the O-O donor, the higher activity was
showed m those Casiopeinas with glycine.
27Lena Ruiz4amhoez et aL Knigth Move m the Periodic Table, from Copper to
Platinum, N-vel Antitumor Mixed "helate C’opper (,ompounds
-rl’hc antincoplastlc aztivity of the Cm;iopeinas and Cisplatin is low for highly mestastatic cell lines like
lcwis Lung Carcinoma and t316 Melanoma
--’l’he tnonochelate copper complexes shown a very low activity comared with those of the Casiopeinas,
these results clearcly indicafcd thatc activity of C.asiopeinas is due to the whole moleculc.
-Casiopeinas keep being a promising resource for the treatment of neoplastic diseases, because have shown
higher activity than the conm.)l da-ug (Cisplatin).
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